FI105477B - 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin enantiomeerit ja menetelmä niiden valmistamiseksi - Google Patents
1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin enantiomeerit ja menetelmä niiden valmistamiseksi Download PDFInfo
- Publication number
- FI105477B FI105477B FI941134A FI941134A FI105477B FI 105477 B FI105477 B FI 105477B FI 941134 A FI941134 A FI 941134A FI 941134 A FI941134 A FI 941134A FI 105477 B FI105477 B FI 105477B
- Authority
- FI
- Finland
- Prior art keywords
- chlorophenyl
- methylphenyl
- piperazine
- phenylmethyl
- formula
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims description 14
- JUQGYTLIFLVABO-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-(4-methylphenyl)sulfonylpiperazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 JUQGYTLIFLVABO-UHFFFAOYSA-N 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 12
- 230000008569 process Effects 0.000 title claims description 9
- -1 (3-methylphenyl)methyl Chemical group 0.000 claims abstract description 20
- MMEIYVXPSXIGET-UHFFFAOYSA-N n-benzyl-4-chloroaniline Chemical compound C1=CC(Cl)=CC=C1NCC1=CC=CC=C1 MMEIYVXPSXIGET-UHFFFAOYSA-N 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910052740 iodine Chemical group 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- HIKIBGRLBOCOAZ-UHFFFAOYSA-N 1-[[1-(4-chlorophenyl)cyclohexa-2,4-dien-1-yl]methyl]piperazine Chemical class C1=CC(Cl)=CC=C1C1(CN2CCNCC2)C=CC=CC1 HIKIBGRLBOCOAZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 230000003287 optical effect Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PTVBBIMKLOMGSY-UHFFFAOYSA-N n,n-bis(2-chloroethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCCl)CCCl)C=C1 PTVBBIMKLOMGSY-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- AOJBACHWNDMRQP-UHFFFAOYSA-N n,n-diethyl-4-methylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(C)C=C1 AOJBACHWNDMRQP-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- LDMXKFMENWDLFN-UHFFFAOYSA-N n,n-bis(2-iodoethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCI)CCI)C=C1 LDMXKFMENWDLFN-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VHFDYFUMWJSVCA-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylpiperazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCNCC1 VHFDYFUMWJSVCA-UHFFFAOYSA-N 0.000 description 1
- QMKYHNMKUFVYCF-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-(2-methylphenyl)sulfonylpiperazine Chemical compound ClC1=CC=C(C=C1)C(N1CCN(CC1)S(=O)(=O)C1=C(C=CC=C1)C)C1=CC=CC=C1 QMKYHNMKUFVYCF-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- KHVRISPYTQIGFL-UHFFFAOYSA-N 2-(benzenesulfonamido)ethyl methanesulfonate Chemical compound C1(=CC=CC=C1)S(=O)(=O)NCCOS(=O)(=O)C KHVRISPYTQIGFL-UHFFFAOYSA-N 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960004578 ethylmorphine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- NHFJDXPINIIUQG-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NHFJDXPINIIUQG-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9305282 | 1993-03-15 | ||
| GB939305282A GB9305282D0 (en) | 1993-03-15 | 1993-03-15 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI941134A0 FI941134A0 (fi) | 1994-03-10 |
| FI941134L FI941134L (fi) | 1994-09-16 |
| FI105477B true FI105477B (fi) | 2000-08-31 |
Family
ID=10732080
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI941134A FI105477B (fi) | 1993-03-15 | 1994-03-10 | 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin enantiomeerit ja menetelmä niiden valmistamiseksi |
| FI991729A FI105914B (fi) | 1993-03-15 | 1999-08-16 | Menetelmä valmistaa farmaseuttisesti vaikuttavaa 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin vasemmalle tai oikealle kiertävää enantiomeeria |
| FI991730A FI105915B (fi) | 1993-03-15 | 1999-08-16 | Menetelmä valmistaa 1-[(4-kloorifenyyli)fenyylimetyyli]-piperatsiinin enantiomeereja |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI991729A FI105914B (fi) | 1993-03-15 | 1999-08-16 | Menetelmä valmistaa farmaseuttisesti vaikuttavaa 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin vasemmalle tai oikealle kiertävää enantiomeeria |
| FI991730A FI105915B (fi) | 1993-03-15 | 1999-08-16 | Menetelmä valmistaa 1-[(4-kloorifenyyli)fenyylimetyyli]-piperatsiinin enantiomeereja |
Country Status (23)
| Country | Link |
|---|---|
| US (17) | US5478941A (cs) |
| EP (3) | EP0955295B1 (cs) |
| JP (3) | JP3267434B2 (cs) |
| KR (1) | KR100322415B1 (cs) |
| AT (2) | ATE193889T1 (cs) |
| AU (1) | AU678426B2 (cs) |
| CA (2) | CA2118859C (cs) |
| DE (2) | DE69424893T2 (cs) |
| DK (1) | DK0617028T3 (cs) |
| ES (2) | ES2221262T3 (cs) |
| FI (3) | FI105477B (cs) |
| GB (1) | GB9305282D0 (cs) |
| GR (1) | GR3034340T3 (cs) |
| HU (1) | HU219230B (cs) |
| NO (2) | NO305908B1 (cs) |
| NZ (1) | NZ260062A (cs) |
| PL (1) | PL178546B1 (cs) |
| PT (1) | PT617028E (cs) |
| RU (1) | RU2118320C1 (cs) |
| SG (1) | SG43683A1 (cs) |
| SI (2) | SI0617028T1 (cs) |
| TW (1) | TW237452B (cs) |
| ZA (1) | ZA941724B (cs) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
| EP0950412A3 (en) * | 1992-09-24 | 2001-05-16 | Sepracor, Inc. | Compositions for treating allergic disorders using (-) cetirizine |
| DK0661975T3 (da) * | 1992-09-24 | 1999-09-27 | Sepracor Inc | Transdermal behandling af nældefeber ved anvendelse af optisk rent (+)-cetirizin |
| GB9305282D0 (en) * | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
| JP3426242B2 (ja) * | 1994-01-14 | 2003-07-14 | 株式会社アズウェル | ジアザシクロアルカンアルキルスルホンアミド誘導体 |
| CN1058638C (zh) * | 1995-06-27 | 2000-11-22 | 中国药品生物制品检定所 | 胞内分枝杆菌变态反应原提取方法 |
| JP3476475B2 (ja) | 1997-06-04 | 2003-12-10 | 株式会社アズウェル | ピペラジンスルホンアミド誘導体およびその塩の製造方法 |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| IL124195A (en) * | 1998-04-23 | 2000-08-31 | Chemagis Ltd | Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid |
| US6432961B1 (en) | 1998-08-18 | 2002-08-13 | Ucb S.A. | Method for preventing the onset of asthma |
| PE20001566A1 (es) * | 1999-03-26 | 2001-02-05 | Ucb Sa | Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas |
| WO2001040211A1 (en) * | 1999-11-30 | 2001-06-07 | EGIS Gyógyszergyár Rt. | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR |
| JP2002249487A (ja) | 2001-02-22 | 2002-09-06 | Sumitomo Chem Co Ltd | ４−（ｔｅｒｔ−ブトキシカルボニル）ピペラジン誘導体、その光学活性な酸付加塩、それらの製造法、およびそれらを用いる光学活性な１−［（置換フェニル）フェニルメチル］ピペラジンの製造法。 |
| US7199241B1 (en) | 2001-05-29 | 2007-04-03 | Ucb, S.A. | Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
| US6977301B1 (en) | 2001-05-29 | 2005-12-20 | Ucb, S.A. | Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
| PE20040167A1 (es) * | 2002-03-28 | 2004-05-26 | Novartis Ag | Amidas del acido sulfamico |
| CN1692105A (zh) * | 2002-12-04 | 2005-11-02 | 雷迪实验室有限公司 | 西替利嗪二盐酸盐多晶型物及其制备方法 |
| WO2004084836A2 (en) * | 2003-03-20 | 2004-10-07 | Rinat Neuroscience Corp. | Methods for treating taxol-induced gut disorder |
| US7577727B2 (en) * | 2003-06-27 | 2009-08-18 | Newisys, Inc. | Dynamic multiple cluster system reconfiguration |
| KR100503443B1 (ko) | 2004-02-02 | 2005-07-22 | 한림제약(주) | 광학적으로 활성인 세티리진 또는 그의 염의 제조방법 |
| MX2007010455A (es) * | 2005-03-03 | 2007-11-08 | Ucb Farchim Sa | Sales de piroglutamato y su uso en la resolucion optica de intermediarios para la sintesis de dextrocetirizina y levocetirizina. |
| HU227074B1 (en) * | 2005-12-08 | 2010-06-28 | Egis Gyogyszergyar Nyrt | An optically active carbamic acid derivative, method for producing the same and use as a pharmaceutical intermediate |
| WO2008110586A2 (en) | 2007-03-12 | 2008-09-18 | Krka, Tovarna Zdravil, D.D., Novo Mesto | New process for the preparation of levocetirizine and intermediates thereof |
| WO2008152650A1 (en) | 2007-06-15 | 2008-12-18 | Symed Labs Limited | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates |
| US20090062305A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched cetirizine |
| US20090082364A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched levocedtirizine |
| KR101427100B1 (ko) | 2007-10-23 | 2014-08-08 | 주식회사 씨트리 | 광학활성을 갖는 1-[(4-클로로페닐)페닐메틸]-피페라진의제조방법 |
| US7989623B2 (en) * | 2007-11-21 | 2011-08-02 | Synthon Bv | Process for making n-(diphenylmethyl)piperazines |
| EP2062881B1 (en) | 2007-11-21 | 2011-02-23 | Synthon B.V. | Process for making N-(diphenylmethyl)piperazines |
| KR100954755B1 (ko) * | 2007-12-17 | 2010-04-27 | 한미약품 주식회사 | (ｒ)-(-)-1-[(4-클로로페닐)페닐메틸]피페라진의 제조방법 |
| AU2009254959B2 (en) * | 2008-06-02 | 2014-01-30 | Cipla Limited | Processes for the synthesis of levocetirizine and intermediates for use therein |
| KR100998067B1 (ko) | 2008-09-08 | 2010-12-03 | 주식회사 삼오제약 | 비스(1-[(4-클로로페닐)페닐메틸]피페라진)-2,3-디벤조일 타르타르산 신규 중간체 염 및 이를 이용한 광학 활성적으로 순수한 1-[(4-클로로페닐)페닐메틸]피페라진을 분리하는 분리방법 |
| US20100145049A1 (en) * | 2008-11-21 | 2010-06-10 | Jie Zhu | Process for making n-(diphenylmethyl)piperazines |
| CA2758729A1 (en) * | 2009-04-22 | 2010-10-28 | Axikin Pharmaceuticals, Inc. | Arylsulfonamide ccr3 antagonists |
| CN101928223A (zh) * | 2009-06-26 | 2010-12-29 | 华东理工大学 | 一种(r)-(-)-4-氯二苯甲胺的拆分方法 |
| WO2012101475A1 (en) | 2011-01-27 | 2012-08-02 | Jubilant Life Sciences Limited | An improved process for the preparation of antihistaminic drugs via a novel carbamate intermediate |
| KR101418404B1 (ko) | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
| WO2013158318A1 (en) | 2012-04-16 | 2013-10-24 | Zemtsov Enterprises, Llc | Formulations and methods for treatment of acne and inflammatory skin conditions |
| CN103613567A (zh) * | 2012-11-09 | 2014-03-05 | 焦作福瑞堂制药有限公司 | 盐酸氯环利嗪的合成工艺 |
| KR102226833B1 (ko) | 2013-06-28 | 2021-03-12 | 한미약품 주식회사 | 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형 |
| CN104045607B (zh) * | 2014-05-21 | 2016-04-13 | 丽珠医药集团股份有限公司 | 一种盐酸西替利嗪的纯化方法 |
| CN111205247B (zh) * | 2020-04-22 | 2020-08-14 | 湖南九典宏阳制药有限公司 | 左旋西替利嗪的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE540057A (cs) * | ||||
| US2899436A (en) * | 1959-08-11 | chjch | ||
| US2709169A (en) * | 1955-05-24 | X c chs | ||
| BE523901A (cs) * | ||||
| CA568380A (en) * | 1959-01-06 | Morren Henri | Ethers of piperazine and method of their preparation | |
| GB752331A (en) * | 1948-09-30 | 1956-07-11 | Abbott Lab | Improvements in or relating to n, n-disubstituted piperazines and process of preparing the same |
| US2861072A (en) * | 1952-07-19 | 1958-11-18 | Abbott Lab | Preparation of piperazine derivatives |
| US2709167A (en) * | 1952-09-10 | 1955-05-24 | Geigy Ag J R | Chromium-containing monoazo dyestuffs |
| US2897436A (en) * | 1954-09-29 | 1959-07-28 | Amchem Prod | Indicating and control apparatus for electrolyte concentration and the like |
| US3406174A (en) * | 1964-10-23 | 1968-10-15 | Sandoz Ag | Benzylsulfamides |
| DK154078C (da) * | 1981-02-06 | 1989-05-22 | Ucb Sa | Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf |
| US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| DE3640247A1 (de) * | 1986-11-25 | 1988-05-26 | Basf Ag | Fungizide cyclohexylamine |
| US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| JP2559463B2 (ja) * | 1988-06-01 | 1996-12-04 | ダイセル化学工業株式会社 | 不斉中心に２個の芳香族基を有する化合物の光学分割方法 |
| JPH0239947A (ja) * | 1988-07-29 | 1990-02-08 | Seikosha Co Ltd | 印字ヘッド |
| GB8827391D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
| US4882432A (en) * | 1989-01-09 | 1989-11-21 | American Home Products Corporation | Polycyclic-carbamic acid piperazinoalkyl esters and amides |
| US5087627A (en) * | 1989-03-15 | 1992-02-11 | Santen Pharmaceutical Co., Ltd. | Agent for treatment of disorders of the cerebro-neural transmission system |
| EP0475251B1 (en) * | 1990-09-10 | 1997-03-26 | Mitsubishi Denki Kabushiki Kaisha | Coding apparatus for digital image data |
| EP0950412A3 (en) | 1992-09-24 | 2001-05-16 | Sepracor, Inc. | Compositions for treating allergic disorders using (-) cetirizine |
| DK0661975T3 (da) * | 1992-09-24 | 1999-09-27 | Sepracor Inc | Transdermal behandling af nældefeber ved anvendelse af optisk rent (+)-cetirizin |
| GB9305282D0 (en) * | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
-
1993
- 1993-03-15 GB GB939305282A patent/GB9305282D0/en active Pending
-
1994
- 1994-03-08 TW TW083102003A patent/TW237452B/zh active
- 1994-03-08 US US08/207,096 patent/US5478941A/en not_active Expired - Lifetime
- 1994-03-09 DE DE69424893T patent/DE69424893T2/de not_active Expired - Fee Related
- 1994-03-09 ES ES99109564T patent/ES2221262T3/es not_active Expired - Lifetime
- 1994-03-09 PT PT94870043T patent/PT617028E/pt unknown
- 1994-03-09 EP EP99109564A patent/EP0955295B1/fr not_active Expired - Lifetime
- 1994-03-09 SI SI9430329T patent/SI0617028T1/xx unknown
- 1994-03-09 EP EP04002438A patent/EP1413307A1/fr not_active Withdrawn
- 1994-03-09 EP EP94870043A patent/EP0617028B1/fr not_active Expired - Lifetime
- 1994-03-09 DE DE69433802T patent/DE69433802T2/de not_active Expired - Fee Related
- 1994-03-09 DK DK94870043T patent/DK0617028T3/da active
- 1994-03-09 AT AT94870043T patent/ATE193889T1/de not_active IP Right Cessation
- 1994-03-09 ES ES94870043T patent/ES2147569T3/es not_active Expired - Lifetime
- 1994-03-09 SI SI9430468T patent/SI0955295T1/xx unknown
- 1994-03-09 AT AT99109564T patent/ATE267185T1/de not_active IP Right Cessation
- 1994-03-09 SG SG1995002010A patent/SG43683A1/en unknown
- 1994-03-10 FI FI941134A patent/FI105477B/fi active
- 1994-03-10 NZ NZ260062A patent/NZ260062A/en not_active IP Right Cessation
- 1994-03-11 NO NO940881A patent/NO305908B1/no not_active IP Right Cessation
- 1994-03-11 PL PL94302565A patent/PL178546B1/pl not_active IP Right Cessation
- 1994-03-11 AU AU57771/94A patent/AU678426B2/en not_active Ceased
- 1994-03-11 HU HU9400727A patent/HU219230B/hu not_active IP Right Cessation
- 1994-03-11 CA CA002118859A patent/CA2118859C/en not_active Expired - Fee Related
- 1994-03-11 CA CA002443216A patent/CA2443216C/en not_active Expired - Fee Related
- 1994-03-11 ZA ZA941724A patent/ZA941724B/xx unknown
- 1994-03-14 RU RU94008618A patent/RU2118320C1/ru active
- 1994-03-14 KR KR1019940005172A patent/KR100322415B1/ko not_active Expired - Fee Related
- 1994-03-14 JP JP04254794A patent/JP3267434B2/ja not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/460,844 patent/US5703082A/en not_active Expired - Fee Related
-
1997
- 1997-10-09 US US08/947,859 patent/US5792770A/en not_active Expired - Fee Related
-
1999
- 1999-01-26 NO NO990351A patent/NO306616B1/no not_active IP Right Cessation
- 1999-07-19 US US09/356,865 patent/US6436942B1/en not_active Expired - Fee Related
- 1999-08-16 FI FI991729A patent/FI105914B/fi active
- 1999-08-16 FI FI991730A patent/FI105915B/fi active
-
2000
- 2000-09-06 GR GR20000402028T patent/GR3034340T3/el not_active IP Right Cessation
-
2001
- 2001-11-22 JP JP2001356849A patent/JP3880842B2/ja not_active Expired - Fee Related
-
2002
- 2002-05-10 US US10/141,933 patent/US20030105112A1/en not_active Abandoned
- 2002-06-06 US US10/162,576 patent/US20030105113A1/en not_active Abandoned
-
2003
- 2003-03-12 US US10/385,522 patent/US20030204089A1/en not_active Abandoned
- 2003-10-07 US US10/679,376 patent/US20040072845A1/en not_active Abandoned
- 2003-12-02 US US10/724,640 patent/US20040122021A1/en not_active Abandoned
- 2003-12-02 US US10/724,611 patent/US20040122023A1/en not_active Abandoned
-
2005
- 2005-04-15 US US11/106,456 patent/US20050182070A1/en not_active Abandoned
- 2005-04-15 US US11/106,613 patent/US20050176732A1/en not_active Abandoned
- 2005-04-15 US US11/106,528 patent/US20050182069A1/en not_active Abandoned
-
2006
- 2006-06-16 US US11/453,987 patent/US20060229319A1/en not_active Abandoned
- 2006-06-16 US US11/453,986 patent/US20060229320A1/en not_active Abandoned
- 2006-07-17 US US11/487,331 patent/US20060252934A1/en not_active Abandoned
- 2006-09-29 JP JP2006266195A patent/JP2006342190A/ja not_active Abandoned
-
2007
- 2007-01-11 US US11/652,092 patent/US20070142400A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI105477B (fi) | 1-[(4-kloorifenyyli)fenyylimetyyli]-4-[(4-metyylifenyyli)sulfonyyli]piperatsiinin enantiomeerit ja menetelmä niiden valmistamiseksi | |
| EP0159566B1 (en) | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | |
| DK162389B (da) | Analogifremgangsmaade til fremstilling af 2-oe4-oe(4,4-dialkyl-2,6-piperidindion-1-yl)butylaa-1-piperazinylaapyrimidiner | |
| TW200817406A (en) | Imidazole amines as inhibitors of β-secretase | |
| EP0330065B1 (en) | Sulfonamide compounds | |
| PT97510A (pt) | Processo de preparacao de novos derivados da 2-metoxifenilpiperazina | |
| TW200918506A (en) | Indane-amine derivatives, their preparation and use as medicaments | |
| WO1992005165A1 (fr) | Derive de diphenylpiperazine et medicament pour organes de l'appareil circulatoire contenant ce compose | |
| JPH04264078A (ja) | ピペラジン誘導体の製造方法 | |
| PL95166B1 (cs) | ||
| EP0314363A2 (en) | Anti-anxiety agents | |
| TW397829B (en) | A morpholine derivatives | |
| AU609681B2 (en) | 3-hydroxy-2-(4-methoxyphenyl)-5-(2-methylaminoethyl)-2, 3-dihydro-5h-1, 5-benzothiazepin-4-one derivatives, their preparation and their application in therapy | |
| NO128773B (cs) | ||
| EP2167479B1 (en) | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | |
| US6608195B2 (en) | Process for the preparation of 2-(4-alkyl-1-piperazinyl)-benzaldehyde and -benzylidenyl compounds | |
| CA1338711C (en) | Ethanone oximes | |
| JPS6028825B2 (ja) | 新規トリアゾ−ル誘導体の製法 | |
| CZ348595A3 (en) | Pharmacologically active enantiomers, process of their preparation, intermediates of the process and their use | |
| PT86424B (pt) | Processo para a preparacao de tetra-hidropirido-indoles substituidos | |
| US20100069389A1 (en) | Novel forms of reboxetine | |
| Li et al. | Combinatorial synthesis of deuterium-enriched (S)-oxybutynin | |
| PT1351950E (pt) | Compostos de isoquinolinil aroil pirrole para o tratamento de distúrbios do sistema nervoso central | |
| HU221731B1 (hu) | Eljárás 1-[(4-klór-fenil)-fenil-metil]-piperazin enantiomerjeinek előállítására | |
| FR2531702A1 (fr) | Derives de phenethyl-1a-phenylperidine-3-propanenitrile, leur preparation et leur application en therapeutique |